Date clarification: The event date in the prompt is July 28, 2026, which is today, not tomorrow. This preview assumes Incyte reports its 2Q26 results and hosts its 2026Q2 earnings call on July 28, 2026.
Incyte enters 2Q26 with a strong operating backdrop but an unusually important accounting and guidance issue: its June 22 settlement with CMS regarding Opzelura. The company disclosed that it expects to record an approximately $246 million one-time, non-cash benefit in 2Q26 from reversing prior accruals, and that Opzelura’s ongoing gross-to-net economics should improve. That makes headline GAAP earnings potentially very strong—but investors should focus primarily on:
The setup is constructive: INCY closed at $118.90 on July 27, up roughly 17% year to date and about 15% since the June 22 CMS settlement disclosure. That performance suggests investors already recognize some value from the settlement, raising the bar for a positive reaction: the company will likely need to demonstrate that the benefit is not merely a one-quarter accounting gain but a meaningful improvement to the long-term Opzelura earnings algorithm.
The June 22 agreement resolved Incyte’s dispute with CMS over the treatment of Opzelura under Medicaid rebate rules. CMS will not apply the line-extension regulation to Opzelura as though it were a line extension of Jakafi.
Incyte said the agreement should produce:
This is the central issue for the call. The headline benefit itself has already been disclosed, so the key incremental information is likely to be:
Investor interpretation: A sizable EPS beat driven solely by the $246 million reversal should be treated differently from a guidance increase supported by recurring Opzelura economics. The latter would be the more important valuation-positive outcome.
Source: Incyte Form 8-K, June 22, 2026.
Opzelura remains Incyte’s most important non-Jakafi commercial asset. In 1Q26, it generated $143 million of sales, up 20% year over year; U.S. sales were $106 million, while international sales were $37 million, up 56% year over year. Management attributed growth to demand in both atopic dermatitis and vitiligo.
For 2026, Incyte’s prior Opzelura net-sales guide was $750 million–$790 million. After 1Q, that implied $607 million–$647 million still required across the final three quarters, or roughly $202 million–$216 million per quarter on average. That is not a 2Q forecast—seasonality and the accounting impact matter—but it illustrates why the second half needs to show a higher Opzelura run rate than 1Q.
Questions for the call
Management previously highlighted that Opzelura had captured 46% of U.S. new patient starts within its relevant branded topical market during 1Q, with new-patient-start volume up more than 30% year over year. Maintaining that demand profile would reinforce the view that Opzelura’s growth is demand-led rather than purely accounting-driven.
Sources: Incyte 1Q26 earnings release and earnings-call transcript, April 28, 2026; Incyte Form 8-K, June 22, 2026.
Jakafi remains the earnings base of the company. In 1Q26, sales were $758 million, up 7% year over year, with paid demand up 6% and growth across myelofibrosis, polycythemia vera, and graft-versus-host-disease indications.
The company’s 2026 Jakafi guide was $3.22 billion–$3.27 billion. After 1Q, that leaves $2.46 billion–$2.51 billion for the remaining three quarters—an average of roughly $821 million–$837 million per quarter. That bridge places particular importance on demand sustainability and the anticipated Jakafi XR launch.
Management expected a U.S. regulatory decision and potential commercial launch of Jakafi XR in mid-2026, and has said XR could represent 10%–30% of the Jakafi franchise by 2029.
What investors need to hear
A clean Jakafi quarter matters because it funds the company’s expanding late-stage development investment. Any material slowdown would overshadow otherwise favorable Opzelura accounting.
Sources: Incyte 1Q26 earnings release and earnings-call transcript, April 28, 2026.
Incyte’s hematology and oncology portfolio generated $204 million in 1Q26, up 116% year over year, led by Niktimvo, Monjuvi/Minjuvi, and Zynyz. Full-year guidance was $800 million–$880 million, which implies an average of roughly $199 million–$225 million per quarter across 2Q–4Q after the $204 million first quarter.
Key 1Q product data:
| Product | 1Q26 sales | YoY growth | What to watch in 2Q |
|---|---|---|---|
| Niktimvo | $55M | 305% | New patient starts, repeat use, duration/persistence, partner economics |
| Monjuvi / Minjuvi | $49M | 67% | Follicular lymphoma uptake and path toward potential 1L DLBCL launch in 2027 |
| Zynyz | $41M | 1,276% | Adoption in squamous cell carcinoma of the anal canal and international expansion |
| Iclusig | $35M | 20% | European demand and FX-adjusted trajectory |
| Pemazyre | $23M | 22% | Stability in smaller oncology base |
Niktimvo is particularly important. Management said it had reached 32% share of the third-line-plus chronic GVHD market within roughly a year of launch, with broad utilization across U.S. transplant centers. Sustained execution could make it a meaningful contributor to the company’s non-Jakafi growth profile.
Source: Incyte 1Q26 earnings release and earnings-call transcript, April 28, 2026.
Before the CMS settlement, Incyte reaffirmed the following 2026 guidance:
| Metric | Prior 2026 guidance |
|---|---|
| Total net sales | $4.77B–$4.94B |
| Jakafi net sales | $3.22B–$3.27B |
| Opzelura net sales | $750M–$790M |
| Hematology & Oncology net sales | $800M–$880M |
| GAAP R&D + SG&A | $3.495B–$3.675B |
| Non-GAAP R&D + SG&A | $3.205B–$3.375B |
Management explicitly said it planned to update guidance following the Opzelura settlement. The outcome could take several forms:
The most relevant measure is not simply whether guidance rises, but how much of any improvement is recurring versus one-time.
Incyte’s HS application for povorcitinib has already been accepted by the FDA. Management believes it could become the first approved oral anti-inflammatory therapy for HS, a market it estimates includes more than 300,000 U.S. patients. In 1Q commentary, management cited a potential $500 million–$1 billion peak-sales opportunity for the asset.
The 2Q call is unlikely to deliver a major new regulatory outcome for povorcitinib, but investors should listen for launch-preparedness details, label expectations, and any change in timing.
INCY’s 2Q26 report is less about whether it beats on EPS and more about whether the CMS settlement structurally improves the company’s medium-term growth and margin profile. The one-time $246 million accounting benefit is known; the investment debate is whether Incyte can convert the resulting Opzelura economics into higher durable revenue, better profitability, and additional capacity to fund its increasingly broad late-stage pipeline.
A favorable report would pair an upgraded outlook with continued commercial strength in Opzelura, Jakafi, and Niktimvo. A weaker outcome would be one where the settlement dominates reported earnings but does not materially change the underlying 2026–27 trajectory.
Research basis: Incyte 1Q26 earnings release and conference-call transcript dated April 28, 2026; Incyte Form 8-K dated June 22, 2026; INCY historical share-price data through July 27, 2026.